Sabrina Bernardez‐Pereira

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes

Denílson Campos de Albuquerque, João David de Souza Neto, Fernando Bacal et al. · Arquivos Brasileiros de Cardiologia · 2015 · 231 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry

Sabrina Bernardez‐Pereira, Renato D. Lópes, Maria Julia Machline Carrion et al. · American Heart Journal · 2014 · 99 citations

Medicine, Cardiology, Clinical Cardiology +9

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure

Wilson Nadruz, Luciana Gioli‐Pereira, Sabrina Bernardez‐Pereira et al. · Heart · 2018 · 33 citations · Full text

Medicine, Cardiology, Health Sciences +15